主要文件

查看所有文档

E2470000

依托度酸

Name: 依托度酸
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

1,8-二乙基-1,3,4,9-四氢吡喃[3,4-b]吲哚-1-乙酸, NSC 282126, 依托度酸

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₇H₂₁NO₃

化学文摘社编号:

41340-25-4

分子量:

287.35

NACRES:

NA.24

PubChem Substance ID:

329799029

UNSPSC Code:

41116107

MDL number:

MFCD00133313

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

etodolac

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12

InChI

1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)

InChI key

NNYBQONXHNTVIJ-UHFFFAOYSA-N

Gene Information

human ... PTGS2(5743)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Etodolac EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

非甾体类抗炎化合物，其是COX-1和COX-2的非选择性抑制剂。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 依托度酸

pictograms

GHS06

signalword

Danger

hcodes

H301

pcodes

P264 - P270 - P301 + P310 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Etodolac: the chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid.

L G Humber

Medicinal research reviews, 7(1), 1-28 (1987-01-01)

Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Tetsuji Takayama et al.

Clinical cancer research : an official journal of the American Association for Cancer Research, 17(11), 3803-3811 (2011-03-10)

On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention

Etodolac clinical pharmacokinetics.

D R Brocks et al.

Clinical pharmacokinetics, 26(4), 259-274 (1994-04-01)

Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due

查看所有相关文献

全球贸易项目编号

货号	GTIN
E2470000	04061833602621